WO2009135306A1 - Colostrum-derived fraction for wound healing and skin care - Google Patents
Colostrum-derived fraction for wound healing and skin care Download PDFInfo
- Publication number
- WO2009135306A1 WO2009135306A1 PCT/CA2009/000627 CA2009000627W WO2009135306A1 WO 2009135306 A1 WO2009135306 A1 WO 2009135306A1 CA 2009000627 W CA2009000627 W CA 2009000627W WO 2009135306 A1 WO2009135306 A1 WO 2009135306A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- colostrum
- composition
- process according
- wound
- formulation
- Prior art date
Links
- 235000021277 colostrum Nutrition 0.000 title claims abstract description 79
- 210000003022 colostrum Anatomy 0.000 title claims abstract description 79
- 230000029663 wound healing Effects 0.000 title claims description 24
- 239000000203 mixture Substances 0.000 claims abstract description 93
- 206010052428 Wound Diseases 0.000 claims abstract description 68
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 51
- 230000008569 process Effects 0.000 claims abstract description 33
- 239000003102 growth factor Substances 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 238000009472 formulation Methods 0.000 claims abstract description 20
- 231100000397 ulcer Toxicity 0.000 claims abstract description 10
- 206010040943 Skin Ulcer Diseases 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 7
- 208000028990 Skin injury Diseases 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 229920001436 collagen Polymers 0.000 claims description 36
- 102000008186 Collagen Human genes 0.000 claims description 34
- 108010035532 Collagen Proteins 0.000 claims description 34
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 30
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 24
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 22
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 231100000241 scar Toxicity 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 239000005862 Whey Substances 0.000 claims description 16
- 102000007544 Whey Proteins Human genes 0.000 claims description 16
- 108010046377 Whey Proteins Proteins 0.000 claims description 16
- 230000008602 contraction Effects 0.000 claims description 16
- 239000012466 permeate Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 108060001132 cathelicidin Proteins 0.000 claims description 11
- 102000014509 cathelicidin Human genes 0.000 claims description 11
- 102000000541 Defensins Human genes 0.000 claims description 10
- 108010002069 Defensins Proteins 0.000 claims description 10
- 102000016943 Muramidase Human genes 0.000 claims description 10
- 108010014251 Muramidase Proteins 0.000 claims description 10
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 10
- 101710088675 Proline-rich peptide Proteins 0.000 claims description 10
- 229960000274 lysozyme Drugs 0.000 claims description 10
- 235000010335 lysozyme Nutrition 0.000 claims description 10
- 239000004325 lysozyme Substances 0.000 claims description 10
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 7
- 235000021240 caseins Nutrition 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 239000005018 casein Substances 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000001728 nano-filtration Methods 0.000 claims description 4
- 238000010257 thawing Methods 0.000 claims description 4
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 229940108461 rennet Drugs 0.000 claims description 3
- 108010058314 rennet Proteins 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 2
- 241000283074 Equus asinus Species 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 abstract description 11
- 206010072170 Skin wound Diseases 0.000 abstract description 5
- 208000025865 Ulcer Diseases 0.000 abstract description 4
- 208000017520 skin disease Diseases 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 19
- 238000010790 dilution Methods 0.000 description 18
- 239000012895 dilution Substances 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 230000001969 hypertrophic effect Effects 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 8
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 8
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000512 collagen gel Substances 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000011632 Caseins Human genes 0.000 description 4
- 108010076119 Caseins Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 4
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000036573 scar formation Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000010388 wound contraction Effects 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 102000012265 beta-defensin Human genes 0.000 description 3
- 108050002883 beta-defensin Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
- 208000002260 Keloid Diseases 0.000 description 2
- 102000010445 Lactoferrin Human genes 0.000 description 2
- 108010063045 Lactoferrin Proteins 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000018568 alpha-Defensin Human genes 0.000 description 2
- 108050007802 alpha-defensin Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000001889 chemoattractive effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
- 235000021242 lactoferrin Nutrition 0.000 description 2
- 229940078795 lactoferrin Drugs 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
- 101000679555 Homo sapiens TOX high mobility group box family member 2 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 102000019361 Syndecan Human genes 0.000 description 1
- 108050006774 Syndecan Proteins 0.000 description 1
- 102100022611 TOX high mobility group box family member 2 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000037369 collagen remodeling Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- JBBPTUVOZCXCSU-UHFFFAOYSA-L dipotassium;2',4',5',7'-tetrabromo-4,7-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [K+].[K+].O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 JBBPTUVOZCXCSU-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000018127 platelet degranulation Effects 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940116157 regranex Drugs 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 101150063569 slgA gene Proteins 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000659 thermocoagulation Effects 0.000 description 1
- 108010034266 theta-defensin Proteins 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Definitions
- the present invention relates to a colostrum-derived mixture enriched in growth factors.
- the invention provides a bovine colostrum fraction for the treatment of skin injury, diseases, wounds or ulcers. More particularly the invention provides a topical or oral composition that includes a pharmaceutically effective amount of bioactive growth factors and antimicrobial peptides originating from bovine colostrum, for the treatment of skin injury, diseases, wounds or ulcers.
- Skin as the outermost organ in the human body, continuously confronts the external environment and serves as a primary defense system or protective barrier against the environment (Lee et al. 2006). In addition to keeping the harsh external environment away from our own critically sensitive internal biological environments, skin acts as a regulator of body temperature and a sealant against fluid loss.
- the protective functions of skin can be classified as physical, thermal, immune, ultraviolet, oxidant radical, antimicrobial and a permeability barrier.
- a scar is the end result or end point of the body to close a wound, and it is a normal process that occurs whenever an injury involves the dermis.
- the ideal end point is total regeneration, with new tissue having the same structural, aesthetical, and functional attributes as the original uninjured skin.
- DOCSQUE 756309 ⁇ l sports injury is a major medical problem, often resulting in adverse aesthetics, loss of function, restriction of tissue movement and/or growth and adverse physiological effects. Current treatments are empirical, unreliable and unpredictable; there are no prescription drugs for the prevention or treatment of scarring (Bayat et al. 2003). [0005] Skin wounds normally heal in a very orderly and efficient manner characterized by four distinct, but overlapping phases; 1) hemostasis, 2) inflammation, 3) proliferation and 4) remodeling (Singer & Clark 1999).
- Tissue repair begins with clot formation and platelet degranulation, which release the growth factors necessary for wound repair.
- Platelet-derived growth factors are biologically active substances that enhance tissue repair mechanisms such as chemotaxis, cell proliferation, angiogenesis, extracellular matrix deposition, and remodeling (Werner & Grose 2003).
- Infiltrating neutrophils cleanse the wounded area of foreign particles and bacteria and are extruded with eschar or phagocytosed by macrophages.
- chemoattractants such as fragments of extracellular-matrix proteins, growth factors, and monocytes chemoattractants protein 1
- monocytes also infiltrate the wound site and become activated macrophages that release various growth factors (Werner & Grose 2003).
- the proliferative phase is characterized by the increased formation of granulation tissue where fibroblasts lay bed of collagen and produces new capillaries, the contraction of the wound (wound edges pull together to reduce defect) and finally epithelialization of the affected area. Growth factors in concert with extracellular-matrix molecules, presumably stimulate fibroblasts of the tissue around the wound to proliferate (Werner & Grose 2003). The formation of new blood vessels is necessary to sustain the newly formed granulation tissue. Wound contraction involves a complex and
- DOCSQUE 756309U superbly orchestrated interaction of cells, extracellular matrix, and cytokines. The contraction probably requires stimulation by growth factors (Werner & Grose 2003). 4) Remodeling
- Collagen remodeling during the transition from granulation tissue to scar is dependent on continued synthesis and catabolism of collagen at a low rate.
- the degradation of collagen in the wound is controlled by several proteolytic enzymes termed matrix metalloproteinases, which are secreted by macrophages, epidermal cells, and endothelial cells, as well as fibroblasts.
- Chronic wounds may be stopped in any of the four phases, commonly; however, disruption occurs in the inflammatory or proliferative phases.
- Many mediators including inflammatory cells, growth factors, proteases and cellular and extracellular elements play an important role in different stages of the healing process. Alterations in one or more of these components may account for the impaired healing observed in chronic wounds. Growth factors and wound healing
- PDGF was the first growth factor to be approved for the treatment of human ulcers (Regranex gel ® ).
- IGF-I and -Il are small peptides, approximately 7 kDa in size, that are structurally similar to insulin.
- IGF-I and -Il are growth factors that have both mitogenic and metabolic actions that participate in the growth, survival and differentiation of a number of cell types and tissues (Cohick & Clemmos 1993, Stewart & Rotwein 1996).
- IGFs are unique among growth factors in that they can act both synergistically, as a hormone, and locally, as autocrine/paracrine factors (Cohick & Clemmos 1993, Stewart & Rotwein 1996, Butler & LeRoith 2001 ).
- liver is the principal source of circulating IGFs, it is now believed that brain, muscle and bone also produce IGFs (Cohick & Clemmos 1993, Stewart & Rotwein 1996, Butler & LeRoith 2001 ).
- IGFBPs IGF-binding proteins
- IGFs are specifically expressed in granulation tissue and several studies have suggested a role of the IGF system in the wound healing abnormalities associated with diabetes and glucocorticoids treatment (Bitar &Labbad 1996, Bitar 2000, Blakytny et al. 2000). More specifically, these studies suggested that a reduced expression of IGFs and/or their receptors leads to impaired wound healing, although this hypothesis has yet to be confirmed by functional studies. Additionally, IGFs act in synergy with other growth factors to promote healing (Werner & Grose 2003).
- IGFBPs The role of IGFBPs is less clear. It has been shown that the co administration of IGFBP-I with IGF-I can enhance the stimulatory wound-healing properties of IGF-I (Tsuboi et al. 1995) and IGF complexes with IGFBP-3 has a greater effect on wound tissue formation than IGF alone (Campbell et al. 1999), suggesting a vital role of IGFBPs in the regulation of IGF-I action at the cellular level.
- Antimicrobial peptides are predominantly small cationic polypeptides that are classified together due to their capacity to inhibit the growth of microbes. As effectors of innate immunity, AMPs directly kill a broad spectrum of bacteria, fungi, and viruses. In addition, these peptides modify the local inflammation response and activate mechanisms of cellular and adaptive immunity (Reddy et al. 2004).
- DOCSQUL 756309M surface of the host DOCSQUL 756309M surface of the host.
- skin peptides play an integral role in stimulating and regulating wound healing and inflammation.
- Two major classes of peptides have been identified in mammalian skin; (1) defensins and (2) cathelicidins.
- the defensins are cationic peptides (MW 3-5 kDa) divided in three subfamilies, ⁇ -, ⁇ -, and circular ⁇ -defensins based on the alignment of the disulphide bonds.
- AMPs of the defensins family exhibit broad activity against gram- negative bacteria, fungi, mycobacteria and enveloped viruses and have been isolated form neutrophils granules, macrophages and some specialized epithelial cells of the small intestine (Yang et al. 2007).
- ⁇ - and ⁇ -defensins show a broad antibacterial activity against gram positive and negative bacteria (Ehcksen et al.
- Defensins also have antiviral properties against adenovirus (Bastian & Schafer 2001), papilloma virus (Buck et al. 2006), human immunodeficiency virus (HIV) (Chang et al. 2005), and herpes simplex virus (Hazrati et al. 2006).
- defensins Although directly antimicrobial in vitro, the effect of defensins on mammalian cells is an important component of how these peptides affect immunity, ⁇ -, ⁇ -defensins modify cell migration and maturation, ⁇ -defensin are chemoattractive for immature-dentritic cells and memory T-cells (Yang et al. 1999), and also induce cytokines and other molecules secreted from host cells, ⁇ -defensin up-regulate the expression of TNF- ⁇ and IL- ⁇ in monocytes (Chaly et al. 2000).
- cathelicidin peptides have broad antimicrobial activity against gram-positive and negative bacteria (Nizet et al. 2001 ), vaccinia virus (Howell et al. 2004), and fungi (Lopez-Garcia 2005).
- Cathelicidin peptides are cationic and, like defensins, thought to directly bind to anionic cell wall and membrane of the microbe, increasing the permeability of the microbe cell wall.
- Cathelicidin also induces cellular signaling and activates keratinocytes and leucocytes.
- Cathelicidin are chemoattractive to neutrophils, monocytes, and T cells and also promote angiogenesis (De Y et al. 2000). Transactivation of epidermal
- DOCSQULi 756309M growth factor receptors by cathelicidin was observed in human epidermal keratinocytes, and this induces keratinocytes migration (Tokumaru et al. 2005).
- PRPs Proline rich peptides isolated from mammals derive from the cathelicidin. PRPs are very small peptide chains (3.5-6 kDa) of less then a dozen amino acids, with proline predominating (up to 50%). PRPs isolated from early sheep colostrum have been shown to have regulatory effects on the immune response (Wieczorek et al. 1979). PRP acts both in vitro and in vivo, and is not species specific. PRP increases permeability of skin vessels (Wieczorek et al. 1979), and causes differentiation of murine thymocytes into functionally active T cells (Januz & Lisowski 1993). It can simultaneously change surface markers and functions of the cell (Wieczorek 1989).
- AMPs enter cells without membrane lysis and, once in the cytoplasm, bind to, and inhibit the activity of specific molecular targets essential to bacterial growth, thereby causing cell death.
- AMPs from mammals exerts other potentially exploitable biological activities, such as induction of syndecan expression in mesenchymal cells and inhibition of the NADPH oxidase activity of neutrophils, suggesting a role of this peptide in wound healing and inflammation (Gennaro et al. 2002).
- Colostrum is the early milk produced by mammals during the first several days post-parturition. Colostrum provides passive immunity to protect the newborn from opportunistic infections while the immune system is developing, as well as to facilitate the growth and immune maturation of the digestive tract and most certainly other tissues (Gopal & Gill 2000).
- Colostrum has a nutrient profile and immunological composition that differs substantially from mature milk.
- macronutrients found in milk such as protein, carbohydrates, fat and micronutrients including vitamins and minerals
- colostrum is rich in immunoglobulins, growth factors cytokines and nucleosides but also in oligosaccharides, antimicrobials, and immune-regulating factors (Thapa 2005).
- the typical composition of bovine colostrum is enumerated in Table 1.
- DOCSQUE 7 5 6309 ⁇ l Colostrum as a source of growth factors
- Colostrum as a source of antimicrobial peptides
- Colostrum provides numerous antimicrobial factors that exhibit both specific and nonspecific bacteriostatic/bactericidal properties.
- Immunoglobulins are among the first line of protection that are delivered to the neonate through suckling and provide passively acquired immunity.
- Other proteins such as the iron-binding protein, lactoferrin (Clare et al. 2003), and enzymes, including lysozyme, and lactoperoxidase play more of a direct role in inhibiting bacterial invasion (Clare & Swaisgood 2000).
- Recently, soluble defensins, cathelicidins, and toll-like receptors (TLRs) have been identified in human milk (Armogida et al. 2004).
- Immunocompetent cell types including macrophages, granulocytes, T and B-lymphocytes are also present in colostrum.
- One thing of interest is the fact that the total antibacterial effect of colostrum is greater than the sum of the individual contributions of immunoglobulin and nonimmunoglobulin defense proteins. This is most likely due, at least in part, to their synergy.
- DOCSQUC 756309U in person with immune-deficiency syndromes, NSAID-induced gastrointestinal disturbances and aspects of the acute phase response that occurs secondary to surgery (Kelly 2003). Furthermore, some authors have claimed that topical application of colostrum has remedi effects on surface wound and other skin related diseases. Other milk-derived products when taken orally or when applied topically have demonstrated therapeutic benefits (Kelly 2003).
- One aspect of the present invention is to provide a process for the preparation or the production of a composition enriched in growth factors from colostrum, and its uses thereof for the treatment of surface wounds and ulcers.
- the process of the invention comprises the following steps of: a') optionally thawing frozen whole colostrum to a temperature of at least about 4 0 C;
- DOCSQUC. 756309U a) precipitating casein from said colostrum and separating curds from colostrum whey; b) heating said colostrum whey to a temperature of greater than 4O 0 C; c) submitting said heated whey to ultra-filtration with a molecular weight cut- off of about 14kDa or less and collecting permeate; d) acidifying said permeate obtained in step c) to a pH of about 3 or above.
- the acidified permeate obtained in step d) is further concentrated with nanofiltration to obtain a liquid composition.
- this liquid composition comprises at least 20 ng/ml of IGF-1 ; less than 5% (w/w) of protein and is substantially free of lysozyme and TGF- ⁇ .
- this liquid composition is freeze-dried to obtain a solid composition.
- this solid composition comprises at least 1 ng of IGF-1 per mg of solid; less than 5% (w/w) of protein and is substantially free of lysozyme and TGF- ⁇ .
- a particularly aspect of the invention provide a composition enriched in antimicrobial peptides of molecular weight of less than about 15kDa, preferably less than 12 kDa, more preferably less than 1OkDa.
- the composition of the invention comprises physiological amount of these low molecular weight peptides.
- composition of the invention is substantially free of lysozyme and/or TGF- ⁇ .
- composition of the invention comprises a total protein concentration of less than 5% (w/w), preferably less than 2% (w/w).
- the liquid composition of the invention comprises at least 20 ng/ml of IGF-1 , particularly, at least about 40 ng/ml.
- the solid composition of the invention comprises at least 1 ng of IGF-1 per mg of solid, particularly, at least about 1.8 ng/mg.
- a further aspect of the invention provides the use of the composition as defined herein for the manufacture of a formulation for the treatment of a wound
- composition is a topical or an oral formulation.
- a further aspect of the invention provides a method for healing a wound while inducing minimal collagen contraction, said method comprising treating said wound with the formulation as defined herein.
- Another aspect of the present invention is to provide a method for treating skin injury and ulcers comprising application to the wound with the liquid composition "as is” or with the topical or oral formulation as defined herein.
- one aspect of the present invention contemplates a method for accelerating wound healing and improving aesthetical presentation of the scars formed in the wound healing process, the method comprising application on the wounded skin an effective amount of a composition or formulation capable of improving wound healing properties.
- Figure 3 Effect of colostrum-derived fraction on collagen synthesis/deposition and soluble collagen release.
- Figure 4. Effect of colostrums-derived fraction on wound contraction.
- Figure 5. Effect of colostrums-derived fraction on wound tissue areas.
- Figure 6. Effect of colostrums-derived fraction on wound thickness.
- Figure 7. Effect of colostrums-derived fraction on collagen deposition
- Figure 8. Effect of colostrums-derived fraction on collagen density.
- Figure 9 Effect of colostrums-derived fraction on tissue ingrowth in PVA sponge.
- Figure 10 Effect of colostrums-derived fraction on scar formation.
- Figure 11 Effect of colostrums-derived fraction on the prevention of hypertrophic scar.
- an effective amount as used herein is intended to mean an amount sufficient to induce a beneficial or desired clinical result.
- An effective amount can be administered in one or more doses.
- an effective amount of growth factors and/or dairy derived proteins, or other composition is an amount that induces a treatment or prophylactic response against at least one wound healing and/or collagen "anti-contraction" responsible factor, in vitro and/or in vivo.
- the terms "individual” or “subject” treated according to this invention is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, rodents, primates, and pets.
- DOCSQUE 756309 ⁇ l DOCSQUE 756309 ⁇ l
- polypeptide and “peptide” are used interchangeably to refer to polymers of amino acids of molecular weight of about 15kDa or less, and may be interrupted by non-amino acids.
- protein refers to polymers of amino acids of molecular weight of more than 15kDa, and may be interrupted by non-amino acids.
- the present invention provides the process as defined herein, wherein the colostrum in step a) is obtained from thawing frozen whole colostrum to a temperature of at least about 4 0 C; preferably about 1O 0 C.
- the present invention provides the process as defined herein, wherein, in step a), the casein and curds are separated by treatment with microbial rennet; or by acid treatment, preferably at pH 4.6.
- the present invention provides the process as defined herein wherein the acidified permeate obtained in step d) is concentrated to obtain a concentrated liquid fraction.
- the present invention provides the process as defined herein, wherein the concentrated liquid fraction is freeze-dried to obtain a solid fraction (powder).
- the present invention provides the process as defined herein, wherein in step b), said colostrum whey is heated to a temperature of at least 45 0 C, preferably at a temperature of at least about 5O 0 C.
- the present invention provides the process as defined herein, wherein in step c), said heated whey is submitted to ultra-filtration with a molecular weight cut-off of about 12kDa or less; preferably about 1OkDa.
- the present invention provides the process as defined herein, wherein in step d) the permeate is acidified at a pH of about 3.5; preferably at a pH of 3.2.
- the present invention provides the process as defined herein, wherein the acidified permeate is concentrated with nanofiltration or any other concentration method.
- the present invention provides the process as defined herein, wherein said colostrum is obtained from: cow, ewe, jenny (donkey's female); goat or buffalo.
- composition derived from colostrum comprising at least 60% of antimicrobial peptides of MW less than 500Da; IGF-1 and a total protein concentration of less than 5% (w/w).
- the present invention provides the composition as defined herein, comprising at least 70% of antimicrobial peptides of MW less than 500Da and further comprising at least 20% (w/w) of antimicrobial peptides of molecular weight between 500Da and 1OkDa of which between 2% and 10% (w/w) is constituted of IGF-1.
- the present invention provides the composition as defined herein, wherein the composition is liquid and comprises at least 20 ng/ml of IGF-1 ; a total protein concentration of less than 2% (w/w) and is substantially free of lysozyme and TGF- ⁇ .
- the present invention provides the composition as defined herein, wherein IGF-1 is present at at least about 40ng/ml.
- the present invention provides the composition as defined herein, wherein the composition is solid (powder) and comprises at least 1 ng of IGF-1 per mg of solid; a total protein concentration of less than 2% (w/w) of protein and is substantially free of lysozyme and TGF- ⁇ .
- the present invention provides the composition as defined herein, wherein the composition is solid (powder) and comprises at least 1 ng of IGF-1 per mg of solid; a total protein concentration of less than 2% (w/w) of protein and is substantially free of lysozyme and TGF- ⁇ .
- the present invention is solid (powder) and comprises at least 1 ng of IGF-1 per mg of solid; a total protein concentration of less than 2% (w/w) of protein and is substantially free of lysozyme and TGF- ⁇ .
- DOCSQUL 756309M provides the composition as defined herein, wherein IGF-1 is present at at least about 1.6ng/mg total solid.
- the present invention provides the composition as defined herein, wherein said peptides below 500Da are present in physiologically effective amounts.
- the present invention provides the composition as defined herein, wherein said peptide of MW less than 500Da is selected from the group consisting of: PDGF; FGF; EGF; VEGF; defensins, cathelicidins, anti-microbial peptides (AMP) and proline- rich peptides (PRP).
- the present invention provides a formulation comprising a composition as defined herein, further comprising a physiologically acceptable excipient; particularly, the formulation is topical or an oral formulation.
- Frozen whole bovine colostrum (less than 48 hrs post-parturition) is slowly thawed to 1O 0 C until complete melting. The fat fraction is then separated from this raw colostrum using a milk separator. The skimmed colostrum is then heated to 35°C and caseins are precipitated with the addition of double strength microbial rennet (Danisco, Madison, Wl, USA) for 20 minutes. The curds are separated by centrifugation from colostrum whey at 65°C.
- the colostrum whey is heated to 50°C and submitted to an ultrafiltration step using a 10,000 molecular weight cut off (MWCO) spinal wound membrane (Parker Process Advanced Filtration, Oxnard, CA, USA).
- MWCO molecular weight cut off
- the ultrafiltration permeate is collected and acidified to pH 3.2.
- the acidified permeate is then concentrated with nanofiltration. Finally, the concentrated acidified permeate is freeze-dried.
- Samples were solubilized in HPLC grade water and then filtrated on 0.2 ⁇ m pore size filters. Samples were then passed trough a TSK-GEL, Guard SWXL (6.0 i.d. x 40 mm) pre-column (Tosoh Biosep LLC, Montgomeryville, PA, USA) and a TSK-GEL, G2000 SWXL (7.8 i.d.
- Human fibroblasts were derived from foreskins and used at passages between 10 and 25. They were maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma Chemical Co.) supplemented with 5% FBS and antibiotics/antifungic. For the cultures in the presence of the compositions to be tested the concentration of FBS was decreased to 0.5%. In monolayer and 3-D culture experiments, fibroblasts were seeded for a few hours in the presence of
- the XTT Cell Proliferation Assay is a colorimetric assay system which measures the reduction of a tetrazolium component (XTT) into soluble formazan product by the mitochondria of viable cells.
- the samples are read using an ELISA plate reader at a wavelength of 450nm. The amount of color produced is directly proportional to the number of viable cells.
- XTT (2,3-bis ⁇ 2methoxy-4-nitro-5-sulfophenyl ⁇ -2H-tetrazolium-5- carboxyanilide inner salt) assay was performed according to the manufacturer's procedure (TOX2, Sigma-Aldrich Canada Ltd., Oakville, Ontario).
- TOX2 Sigma-Aldrich Canada Ltd., Oakville, Ontario
- cells were seeded at 2.5x10 4 cells/cm 2 for fibroblasts and endothelial cells both in 24 multi-well plates. After 2-4 hrs, cell cultures were rinsed once and media supplemented with only 0.5% FBS containing the different dilutions (1 :1000, 1 :100, 1 :10 and 1 :1 ) of each composition to be tested were introduced.
- DOCSQUL 756309M measured with a fluorometer (Spectra Max 340Pe molecular Devices, Sunnyvale,
- CA CA
- the 1 :1 dilution of the fraction enhanced significantly the cell growth compared to control value (P ⁇ 0.05).
- the lowest dilution tested (1 :0.5) did also enhance cell growth significantly in comparison to the control (P ⁇ 0.05).
- the highest dilutions tested (1 :10 and 1 :5) were not different from the control value.
- Example 4-Collagen contraction [0083] Fibroblasts were mixed in collagen solution prior to gel formation at a density of 5 x 10 4 cells per 500 ⁇ l gel in wells of 24 multiwell plates. Collagen gels were made by mixing a rat tail tendon collagen solution (3.0 mg/ml) with a solution containing culture medium (DMEM 5x sans NaHCO 3 ), FBS, 0.26M NaHCO 3 , 1 N NaOH and the suspension of cells as previously described by Elsdale & Bard (1972). Briefly the formula was the following:
- DOCSQUE 756309M medium was changed, cell cultures rinsed and the different compositions were diluted in culture medium supplemented with 0.5% FBS. Composition was introduced daily for 4 consecutive days. Triplicate samples were analyzed. By 24 hrs the gels were released from wells and left floating in order to trigger the collagen contraction by fibroblasts. Medium was changed at day 2. After 4 days, images of the gels were taken and quantified using an image analysis system (Image J). The values of the areas occupied by gels were expressed in mm 2 according to scale setting.
- Fibroblasts were seeded at 1x10 5 cells per well of 6 multi-well plates in serum-supplemented medium. As described earlier, medium was changed after 2- 4hrs of incubation with a low-serum-supplemented (0.5% FBS) medium containing the composition to be tested. Fibroblast cell cultures were labeled by introducing 1.5 ⁇ Ci/ml [ 3 H]-proline (Perkin Elmer) in medium after 4 hrs post-cell seeding and then every other day at medium changes for 7 days in monolayer cell cultures. The labeling medium contained 10 ⁇ g/ml of ascorbate. At each medium change, media were pooled (medium pool) corresponding to most soluble collagen that has been released form the cells.
- cell-matrix pool The latter consisted mainly of insoluble collagen that has been deposited by the cells forming the extracellular matrix around the fibroblasts.
- EDTA protease inhibitor cocktail
- DOCSQUL 756309M were frozen to be freeze-dried in a freeze-drying apparatus (Labconco). Dried samples were rehydrated in a 4%SDS solution in 5mM TRIS (pH 8.0) while keeping an equal final volume to all samples. For each condition, duplicate samples from the cell-matrix pool and those from the medium pool were counted separately in a liquid scintillation counter (Ultima Gold, Perkin-Elmer). Values were counted in dpm. The compositions were changed on a daily basis for 6 days.
- the two highest dilutions tests (1 :10 and 1 :5) of the colostrum-derived fraction increased amount of collagen and deposition in the cell- matrix pool rather than releasing it in soluble form.
- the effect of the colostrum-derived fraction seems to have two distinct activities depending on its dilutions. The proliferative activity is prone at lower dilutions, whereas collagen metabolic activity is expressed at higher dilutions.
- the colostrum-derived fraction appears to have interesting properties not only on fibroblast growth and synthetic activities, but also on the remodeling of pre- existing collagen.
- Collagen gel contraction is a phenomenon that has been reported as a physical arrangement of pre-existing collagen fibrils ⁇ Guidry and Grinnell, 1985). This is due to direct contact between fibroblasts that adhere strongly to the extracellular matrix and remodel the fibrils.
- the collagen synthesis in collagen gel has been found slightly diminished, as well as the DNA replication, compared to that observed in monolayer cell culture (Mauch et ai, 1988; Nusgens et al., 1984). This phenomenon may be largely due to the presence of collagen fibrils around the cells that down-regulate cell activity as observed in normal connective tissue.
- DOCSQUE: 7S6309M thought that the present colostrum-derived fraction contains some of these molecules that correspond to antagonist on the matrix contraction and remodelling.
- the collagen gel contraction assay is a model relative to the physiopathology of wound healing, scar formation and tissue remodeling, the research and development of agonists and antagonists is incomplete.
- the present fraction is a potential antagonist product, especially as it facilitates also cell growth and collagen synthesis as shown in specific in vitro experimental conditions.
- This composition has potential applications in plastic and reconstructive surgery to treat scar tissues. Indeed, recurrence of excessive remodeled scar tissues (e.g., keloids, hypertrophic scar tissues) after surgery represents an important issue. Furthermore, such composition may find application not only in wound healing but also in fibrotic reaction.
- the present fraction may also find an application in skin ulcers since rebuilding collagen matrix in the wound is also important to consider in such cases.
- the wound model consisted in the creation by scalpel incision of one large open full-thickness wound on each flank of each animal, close to the spinal cord. Each wound area had a 2.5 cm length along the cranio-caudal axis and 2cm large. The whole connective tissue was removed to insure no residue left at the bottom. The animals received, 1hr before surgery, a subcutaneous injection of an analgesic
- DOCSQUB 756309M (Buprenorphine®, 0.05mg/kg) and a Ringer's lactate solution at a volume corresponding to 1/10 th of their weights.
- the animals were anesthetised by isofluorane under oxygen. Surgery was performed in sterile conditions. The skin was aseptized with hibitane, 70% alcohol, and proviodine. Animals received for 2 days after surgery an analgesic at the same dose as described earlier at 12hrs interval. Animals were weighed periodically at dressing change without the dressing to compare with the initial weight performed one day before surgery. All animals grew in an exponential manner as expected in a normal guinea pig development.
- the PVA (Polyvinyl alcohol) sponge model is used for studying granulation and reparative tissue ingrowth. Tissue grows within its interstices shortly after implantation. This model is highly reproducible and is a biologically valid model for studying healing responses.
- Spraque Dawley rats were used for this implantation model.
- a dorsal median incision (rostral) was performed in the skin down to the aponevrosis, and
- DOCSQUE 756309M then two subcutaneous pockets (one on each side) were made. Each wound area was 1x1 cm. A PVA sponge was introduced in each pocket and the skin was sutured (4/0 monofilaments). Sponges were far from the skin incision to avoid any interference. Specimens were retrieved at days 8 and 15 to see the speed of tissue ingrowth. After 8 and 15 days, implants were retrieved, fixed in formaldehyde and processed for histological sections which was stained with hematoxylin, phloxin, saffron and Hoechst 33342 to mark the nuclei and the sections of day 15 were also stained with picro-sirius to visualize the collagen deposition.
- Wound healing is a fundamental complex-tissue reaction leading to skin reconstitution. Alterations in the orchestrated wound healing process result in hypertrophic or keloid scarring. Although hypertrophic scarring commonly occurs following burns, many aspects such as incidence of an optimal treatment for scar hypertrophy remain unclear. Hypertrophic scar is associated with polarized Th2 systemic response to injury that leads to increased T cells and their Th2 fibrogenic cytokines in tissues and the development of fibrosis and hypertrophic scars.
- Bioactive compounds of the composition were concentrated by dehydration with speed-vacuum. The samples were frozen and applied in a speed vacuum with a pressure of 100 milliTorr. A concentration of almost 30 times was achieved. This concentrated fraction was named speed-vaccum IM.
- the wound model consisted in the creation by scalpel incision of two open full-thickness wounds on each flank of each animal, close to the spinal cord. Each wound area had a 1x1 cm. If necessary, haemostasis was insured by compression with a gaze and thermocoagulation. The whole connective tissue was removed to ensure no residue left at the bottom.
- the day of surgery the animals received, 1 hr before surgery, a subcutaneous injection of an analgesic (Buprenorphine®, 0.05mg/kg) and a Ringer's lactate solution at a volume corresponding to 1/10 th of their weights.
- an analgesic Buprenorphine®, 0.05mg/kg
- a Ringer's lactate solution at a volume corresponding to 1/10 th of their weights.
- the animals were anesthetised by isofluorane under oxygen. Surgery was performed in sterile conditions.
- the skin was aseptized with hibitane, 70% alcohol, and proviodine.
- the respective wound was covered with a polyurethane sheet (Tegaderm) and the animals wrapped in gauzes and elastoplast to protect the wounds for 5 days. After 5 days the dressing was renewed in the same manner.
- DOCSQUE 756309U 39 Tsuboi R, Shi CM, Sato C, Cox GN, Ogawa H. Co-administration of insulin- like growth factor (IGF)-I and IGF-binding protein-1 stimulates wound healing in animal models. J Invest Dermatol. 1995; 104(2): 199-203.
- IGF insulin-like growth factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Water Supply & Treatment (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a colostrum-derived mixture enriched in growth factors, particularly, a bovine colostrum fraction in topical or oral formulations for the treatment of skin injury, diseases, wounds or ulcers. The invention also provide a process for the preparation or the production of a composition enriched in growth factors from colostrum, and its uses thereof for the treatment of surface wounds and ulcers.
Description
COLOSTRUM-DERIVED FRACTION FOR WOUND
HEALING AND SKIN CARE
FIELD OF INVENTION
[0001] The present invention relates to a colostrum-derived mixture enriched in growth factors. Particularly, the invention provides a bovine colostrum fraction for the treatment of skin injury, diseases, wounds or ulcers. More particularly the invention provides a topical or oral composition that includes a pharmaceutically effective amount of bioactive growth factors and antimicrobial peptides originating from bovine colostrum, for the treatment of skin injury, diseases, wounds or ulcers.
BACKGROUND Skin function
[0002] Skin, as the outermost organ in the human body, continuously confronts the external environment and serves as a primary defense system or protective barrier against the environment (Lee et al. 2006). In addition to keeping the harsh external environment away from our own critically sensitive internal biological environments, skin acts as a regulator of body temperature and a sealant against fluid loss. The protective functions of skin can be classified as physical, thermal, immune, ultraviolet, oxidant radical, antimicrobial and a permeability barrier. [0003] Following an injury (ulcer, cut, laceration, gash, tear, scrape, abrasion, scratch, floor burn, bruise, bite, UV radiation or excessive pressure), loss of the integrity of large portions of the skin may lead to major disability or even death due to an increased susceptibility to fungus, bacteria, and viral infections.
Skin wound healing [0004] A scar is the end result or end point of the body to close a wound, and it is a normal process that occurs whenever an injury involves the dermis. The ideal end point is total regeneration, with new tissue having the same structural, aesthetical, and functional attributes as the original uninjured skin. However, in man and domestic animals, unstructured scarring in the skin after trauma, surgery, burns or
DOCSQUE: 756309\l
sports injury is a major medical problem, often resulting in adverse aesthetics, loss of function, restriction of tissue movement and/or growth and adverse physiological effects. Current treatments are empirical, unreliable and unpredictable; there are no prescription drugs for the prevention or treatment of scarring (Bayat et al. 2003). [0005] Skin wounds normally heal in a very orderly and efficient manner characterized by four distinct, but overlapping phases; 1) hemostasis, 2) inflammation, 3) proliferation and 4) remodeling (Singer & Clark 1999).
1) Hemostasis
[0006] Tissue repair begins with clot formation and platelet degranulation, which release the growth factors necessary for wound repair. Platelet-derived growth factors are biologically active substances that enhance tissue repair mechanisms such as chemotaxis, cell proliferation, angiogenesis, extracellular matrix deposition, and remodeling (Werner & Grose 2003).
2) Inflammation [0007] Infiltrating neutrophils cleanse the wounded area of foreign particles and bacteria and are extruded with eschar or phagocytosed by macrophages. In response to specific chemoattractants, such as fragments of extracellular-matrix proteins, growth factors, and monocytes chemoattractants protein 1 , monocytes also infiltrate the wound site and become activated macrophages that release various growth factors (Werner & Grose 2003).
3) Proliferation
[0008] Within hours after injury, the proliferation phase begins. The proliferative phase is characterized by the increased formation of granulation tissue where fibroblasts lay bed of collagen and produces new capillaries, the contraction of the wound (wound edges pull together to reduce defect) and finally epithelialization of the affected area. Growth factors in concert with extracellular-matrix molecules, presumably stimulate fibroblasts of the tissue around the wound to proliferate (Werner & Grose 2003). The formation of new blood vessels is necessary to sustain the newly formed granulation tissue. Wound contraction involves a complex and
DOCSQUE: 756309U
superbly orchestrated interaction of cells, extracellular matrix, and cytokines. The contraction probably requires stimulation by growth factors (Werner & Grose 2003). 4) Remodeling
[0009] Collagen remodeling during the transition from granulation tissue to scar is dependent on continued synthesis and catabolism of collagen at a low rate. The degradation of collagen in the wound is controlled by several proteolytic enzymes termed matrix metalloproteinases, which are secreted by macrophages, epidermal cells, and endothelial cells, as well as fibroblasts.
[0010] Chronic wounds may be stopped in any of the four phases, commonly; however, disruption occurs in the inflammatory or proliferative phases. Many mediators including inflammatory cells, growth factors, proteases and cellular and extracellular elements play an important role in different stages of the healing process. Alterations in one or more of these components may account for the impaired healing observed in chronic wounds. Growth factors and wound healing
[0011] As suggested above, and as reviewed by Werner & Grose (2003), growth factors are involved in all steps of wound healing. Furthermore, multiple studies have demonstrated a beneficial effect of exogenous growth factors like PDGF, FGF, EGF, VEGF, TGF and IGF for wound healing (Werner & Grose 2003). In fact, PDGF was the first growth factor to be approved for the treatment of human ulcers (Regranex gel®).
Insulin-like growth factor
[0012] IGF-I and -Il are small peptides, approximately 7 kDa in size, that are structurally similar to insulin. IGF-I and -Il are growth factors that have both mitogenic and metabolic actions that participate in the growth, survival and differentiation of a number of cell types and tissues (Cohick & Clemmos 1993, Stewart & Rotwein 1996). IGFs are unique among growth factors in that they can act both synergistically, as a hormone, and locally, as autocrine/paracrine factors (Cohick & Clemmos 1993, Stewart & Rotwein 1996, Butler & LeRoith 2001 ).
DOCSQUIi: 756309M
- A - Although liver is the principal source of circulating IGFs, it is now believed that brain, muscle and bone also produce IGFs (Cohick & Clemmos 1993, Stewart & Rotwein 1996, Butler & LeRoith 2001 ).
[0013] In vivo IGFs are found complexed with specific IGF-binding proteins (IGFBPs) (Shimasaki & Ling 1991 ). Most IGF-I present in the circulation as part of a 150-kDa complex, comprising IGFBP-3 and an acid-labile subunit, which is thought to regulate the bioavailability of IGF to the tissues and to prolong the half-life of IGFs (Jones & Clemmons 1995).
[0014] IGFs are specifically expressed in granulation tissue and several studies have suggested a role of the IGF system in the wound healing abnormalities associated with diabetes and glucocorticoids treatment (Bitar &Labbad 1996, Bitar 2000, Blakytny et al. 2000). More specifically, these studies suggested that a reduced expression of IGFs and/or their receptors leads to impaired wound healing, although this hypothesis has yet to be confirmed by functional studies. Additionally, IGFs act in synergy with other growth factors to promote healing (Werner & Grose 2003).
[0015] The role of IGFBPs is less clear. It has been shown that the co administration of IGFBP-I with IGF-I can enhance the stimulatory wound-healing properties of IGF-I (Tsuboi et al. 1995) and IGF complexes with IGFBP-3 has a greater effect on wound tissue formation than IGF alone (Campbell et al. 1999), suggesting a vital role of IGFBPs in the regulation of IGF-I action at the cellular level.
Antimicrobial peptides and wound healing
[0016] Antimicrobial peptides (AMPs) are predominantly small cationic polypeptides that are classified together due to their capacity to inhibit the growth of microbes. As effectors of innate immunity, AMPs directly kill a broad spectrum of bacteria, fungi, and viruses. In addition, these peptides modify the local inflammation response and activate mechanisms of cellular and adaptive immunity (Reddy et al. 2004).
[0017] Human skin produces antimicrobial agents that form an innate epithelial chemical shield. These endogenous AMPs are molecules produced by the epithelial
DOCSQUL 756309M
surface of the host. In addition skin peptides play an integral role in stimulating and regulating wound healing and inflammation. Two major classes of peptides have been identified in mammalian skin; (1) defensins and (2) cathelicidins.
[0018] The defensins are cationic peptides (MW 3-5 kDa) divided in three subfamilies, α-, β-, and circular θ-defensins based on the alignment of the disulphide bonds. AMPs of the defensins family exhibit broad activity against gram- negative bacteria, fungi, mycobacteria and enveloped viruses and have been isolated form neutrophils granules, macrophages and some specialized epithelial cells of the small intestine (Yang et al. 2007). [0019] More specifically, α- and β-defensins show a broad antibacterial activity against gram positive and negative bacteria (Ehcksen et al. 2005, Ganz et al. 1985), and have antifungal activity (Hoover et al. 2003). Defensins also have antiviral properties against adenovirus (Bastian & Schafer 2001), papilloma virus (Buck et al. 2006), human immunodeficiency virus (HIV) (Chang et al. 2005), and herpes simplex virus (Hazrati et al. 2006). Although directly antimicrobial in vitro, the effect of defensins on mammalian cells is an important component of how these peptides affect immunity, α-, β-defensins modify cell migration and maturation, β-defensin are chemoattractive for immature-dentritic cells and memory T-cells (Yang et al. 1999), and also induce cytokines and other molecules secreted from host cells, α-defensin up-regulate the expression of TNF-α and IL-β in monocytes (Chaly et al. 2000).
[0020] The amphipathic structure and cationic charge of cathelicidin enable the latter to interact in the aqueous environment, the lipid-rich membrane, and bind negatively charged bacterial membranes. Cathelicidin peptides have broad antimicrobial activity against gram-positive and negative bacteria (Nizet et al. 2001 ), vaccinia virus (Howell et al. 2004), and fungi (Lopez-Garcia 2005). Cathelicidin peptides are cationic and, like defensins, thought to directly bind to anionic cell wall and membrane of the microbe, increasing the permeability of the microbe cell wall. Cathelicidin also induces cellular signaling and activates keratinocytes and leucocytes. Cathelicidin are chemoattractive to neutrophils, monocytes, and T cells and also promote angiogenesis (De Y et al. 2000). Transactivation of epidermal
DOCSQULi: 756309M
growth factor receptors by cathelicidin was observed in human epidermal keratinocytes, and this induces keratinocytes migration (Tokumaru et al. 2005).
[0021] All Proline rich peptides (PRPs) isolated from mammals derive from the cathelicidin. PRPs are very small peptide chains (3.5-6 kDa) of less then a dozen amino acids, with proline predominating (up to 50%). PRPs isolated from early sheep colostrum have been shown to have regulatory effects on the immune response (Wieczorek et al. 1979). PRP acts both in vitro and in vivo, and is not species specific. PRP increases permeability of skin vessels (Wieczorek et al. 1979), and causes differentiation of murine thymocytes into functionally active T cells (Januz & Lisowski 1993). It can simultaneously change surface markers and functions of the cell (Wieczorek 1989).
[0022] Evidence is accumulating that AMPs enter cells without membrane lysis and, once in the cytoplasm, bind to, and inhibit the activity of specific molecular targets essential to bacterial growth, thereby causing cell death. AMPs from mammals, exerts other potentially exploitable biological activities, such as induction of syndecan expression in mesenchymal cells and inhibition of the NADPH oxidase activity of neutrophils, suggesting a role of this peptide in wound healing and inflammation (Gennaro et al. 2002).
Colostrum [0023] Colostrum is the early milk produced by mammals during the first several days post-parturition. Colostrum provides passive immunity to protect the newborn from opportunistic infections while the immune system is developing, as well as to facilitate the growth and immune maturation of the digestive tract and most certainly other tissues (Gopal & Gill 2000). [0024] Colostrum has a nutrient profile and immunological composition that differs substantially from mature milk. In addition to macronutrients found in milk such as protein, carbohydrates, fat and micronutrients including vitamins and minerals, colostrum is rich in immunoglobulins, growth factors cytokines and nucleosides but also in oligosaccharides, antimicrobials, and immune-regulating factors (Thapa 2005). The typical composition of bovine colostrum is enumerated in Table 1.
DOCSQUE: 756309\l
Colostrum as a source of growth factors
[0025] The presence of growth factors was first demonstrated in human colostrum and milk during the 1980's and then in bovine colostrum, milk and whey (Gauthier et al. 2006). Of significant interest is the fact that bovine growth factors found in colostrum are almost identical to that of human in both structures and functions. Specifically, colostrum represents an important source of EGF, IGF-I and II, FGF, PDGF, TGF, but also of interleukins and interferons (Table 1).
Colostrum as a source of antimicrobial peptides
[0026] Colostrum provides numerous antimicrobial factors that exhibit both specific and nonspecific bacteriostatic/bactericidal properties. Immunoglobulins are among the first line of protection that are delivered to the neonate through suckling and provide passively acquired immunity. Other proteins, such as the iron-binding protein, lactoferrin (Clare et al. 2003), and enzymes, including lysozyme, and lactoperoxidase play more of a direct role in inhibiting bacterial invasion (Clare & Swaisgood 2000). Recently, soluble defensins, cathelicidins, and toll-like receptors (TLRs) have been identified in human milk (Armogida et al. 2004).
[0027] Immunocompetent cell types, including macrophages, granulocytes, T and B-lymphocytes are also present in colostrum. One thing of interest is the fact that the total antibacterial effect of colostrum is greater than the sum of the individual contributions of immunoglobulin and nonimmunoglobulin defense proteins. This is most likely due, at least in part, to their synergy.
Clinical uses of colostrum
[0028] The use of colostrum for the treatment of illness and for the maintenance of well-being dates back thousands of years. The Ayurvedic physicians and the Rishis of India have been using colostrum for medicinal purposes since cows have become domesticated. The remarkable thing about colostrum is that all these substances act synergistically in such a way as to enhance the overall effect of each individual component.
[0029] Available evidence suggests a beneficial effect of oral supplementation of colostrum in improving body composition, aspects of athletic performance, diarrhea
DOCSQUC 756309U
in person with immune-deficiency syndromes, NSAID-induced gastrointestinal disturbances and aspects of the acute phase response that occurs secondary to surgery (Kelly 2003). Furthermore, some authors have claimed that topical application of colostrum has benefic effects on surface wound and other skin related diseases. Other milk-derived products when taken orally or when applied topically have demonstrated therapeutic benefits (Kelly 2003).
Table 1. Composition of human and bovine colostrum. afrom Solomon 2002, bfrom Gauthier et al. 2006. Components
Water 78 %a
Carbohydrates 3.1 % a
Fat 3.6 % a
Protein 14.3 % a
Immunoglobulins
IgG 77 mg/ml a
IgM 4.9 mg/ml a slgA 4.4 mg/ml a
Lactoferrin + a
Lysozyme + a
Lactoperoxidase + a
Growth factors
SUMMARY OF THE INVENTION
[0030] One aspect of the present invention is to provide a process for the preparation or the production of a composition enriched in growth factors from colostrum, and its uses thereof for the treatment of surface wounds and ulcers.
[0031] More particularly, the process of the invention comprises the following steps of: a') optionally thawing frozen whole colostrum to a temperature of at least about 40C;
DOCSQUC. 756309U
a) precipitating casein from said colostrum and separating curds from colostrum whey; b) heating said colostrum whey to a temperature of greater than 4O0C; c) submitting said heated whey to ultra-filtration with a molecular weight cut- off of about 14kDa or less and collecting permeate; d) acidifying said permeate obtained in step c) to a pH of about 3 or above.
[0032] Optionally, the acidified permeate obtained in step d) is further concentrated with nanofiltration to obtain a liquid composition. Particularly, this liquid composition comprises at least 20 ng/ml of IGF-1 ; less than 5% (w/w) of protein and is substantially free of lysozyme and TGF-β.
[0033] Further optionally, this liquid composition is freeze-dried to obtain a solid composition. Particularly, this solid composition comprises at least 1 ng of IGF-1 per mg of solid; less than 5% (w/w) of protein and is substantially free of lysozyme and TGF-β. [0034] A particularly aspect of the invention provide a composition enriched in antimicrobial peptides of molecular weight of less than about 15kDa, preferably less than 12 kDa, more preferably less than 1OkDa. Particularly, the composition of the invention comprises physiological amount of these low molecular weight peptides.
[0035] More particularly, the composition of the invention is substantially free of lysozyme and/or TGF-β.
[0036] Particularly, the composition of the invention comprises a total protein concentration of less than 5% (w/w), preferably less than 2% (w/w).
[0037] More particularly, the liquid composition of the invention comprises at least 20 ng/ml of IGF-1 , particularly, at least about 40 ng/ml. [0038] More particularly, the solid composition of the invention comprises at least 1 ng of IGF-1 per mg of solid, particularly, at least about 1.8 ng/mg.
[0039] A further aspect of the invention provides the use of the composition as defined herein for the manufacture of a formulation for the treatment of a wound
DOCSQUb 756309M
and/or facilitating and/or accelerating wound healing while inducing minimal collagen contraction. Particularly, the composition is a topical or an oral formulation.
[0040] A further aspect of the invention provides a method for healing a wound while inducing minimal collagen contraction, said method comprising treating said wound with the formulation as defined herein.
[0041] Another aspect of the present invention is to provide a method for treating skin injury and ulcers comprising application to the wound with the liquid composition "as is" or with the topical or oral formulation as defined herein.
[0042] Accordingly, one aspect of the present invention contemplates a method for accelerating wound healing and improving aesthetical presentation of the scars formed in the wound healing process, the method comprising application on the wounded skin an effective amount of a composition or formulation capable of improving wound healing properties.
[0043] Someone skilled in the art will recognize the type of skin injury or ulcers that can be treated with the method and/or composition and/or formulation of the present invention and may include, amongst others, skin surface wounds, surgery wounds, burns, diabetic ulcers and pressure sores.
DETAILED DESCRIPTION OF THE INVENTION [0044] The present invention now will be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention, may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
Brief description of the drawings
[0045] Figure 1. Effect of colostrum-derived fraction on fibroblasts metabolic activity
(XTT assay).
DOCSQUE. 756309M
[0046] Figure 2. Effect of colostrum-derived fraction on collagen contraction.
[0047] Figure 3. Effect of colostrum-derived fraction on collagen synthesis/deposition and soluble collagen release.
[0048] Figure 4. Effect of colostrums-derived fraction on wound contraction. [0049] Figure 5. Effect of colostrums-derived fraction on wound tissue areas. [0050] Figure 6. Effect of colostrums-derived fraction on wound thickness. [0051] Figure 7. Effect of colostrums-derived fraction on collagen deposition [0052] Figure 8. Effect of colostrums-derived fraction on collagen density.
[0053] Figure 9. Effect of colostrums-derived fraction on tissue ingrowth in PVA sponge.
[0054] Figure 10. Effect of colostrums-derived fraction on scar formation.
[0055] Figure 11. Effect of colostrums-derived fraction on the prevention of hypertrophic scar.
Definitions
[0056] For the purpose of the present invention the following terms are defined below. The expression "effective amount" as used herein is intended to mean an amount sufficient to induce a beneficial or desired clinical result. An effective amount can be administered in one or more doses. For purposes of this invention, an effective amount of growth factors and/or dairy derived proteins, or other composition is an amount that induces a treatment or prophylactic response against at least one wound healing and/or collagen "anti-contraction" responsible factor, in vitro and/or in vivo.
[0057] The terms "individual" or "subject" treated according to this invention is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, rodents, primates, and pets.
DOCSQUE 756309\l
[0058] The term "substantially free" as used herein is intended to mean an amount that is substantially reduced from the original amount in which this constituent is found in colostrum. Particularly, when referring to lysozyme of TGF-β, the term "substantially free" means less than 10% of the original amount, preferably, less than 5% of the original amount, more preferably, less than 2% of the original amount, most preferably in trace amount.
[0059] The terms "polypeptide" and "peptide" are used interchangeably to refer to polymers of amino acids of molecular weight of about 15kDa or less, and may be interrupted by non-amino acids. [0060] The term "protein" refers to polymers of amino acids of molecular weight of more than 15kDa, and may be interrupted by non-amino acids.
Description of particular embodiments
[0061] Particularly, the present invention provides the process as defined herein, wherein the colostrum in step a) is obtained from thawing frozen whole colostrum to a temperature of at least about 40C; preferably about 1O0C.
[0062] Particularly, the present invention provides the process as defined herein, wherein, in step a), the casein and curds are separated by treatment with microbial rennet; or by acid treatment, preferably at pH 4.6. [0063] Particularly, the present invention provides the process as defined herein wherein the acidified permeate obtained in step d) is concentrated to obtain a concentrated liquid fraction.
[0064] Particularly, the present invention provides the process as defined herein, wherein the concentrated liquid fraction is freeze-dried to obtain a solid fraction (powder).
[0065] Particularly, the present invention provides the process as defined herein, wherein in step b), said colostrum whey is heated to a temperature of at least 450C, preferably at a temperature of at least about 5O0C.
DOCSQUE: 756309U
[0066] Particularly, the present invention provides the process as defined herein, wherein in step c), said heated whey is submitted to ultra-filtration with a molecular weight cut-off of about 12kDa or less; preferably about 1OkDa.
[0067] Particularly, the present invention provides the process as defined herein, wherein in step d) the permeate is acidified at a pH of about 3.5; preferably at a pH of 3.2.
[0068] Particularly, the present invention provides the process as defined herein, wherein the acidified permeate is concentrated with nanofiltration or any other concentration method. [0069] Particularly, the present invention provides the process as defined herein, wherein said colostrum is obtained from: cow, ewe, jenny (donkey's female); goat or buffalo.
[0070] In a particular aspect of the invention, there is provided a composition derived from colostrum comprising at least 60% of antimicrobial peptides of MW less than 500Da; IGF-1 and a total protein concentration of less than 5% (w/w).
[0071] Particularly, the present invention provides the composition as defined herein, comprising at least 70% of antimicrobial peptides of MW less than 500Da and further comprising at least 20% (w/w) of antimicrobial peptides of molecular weight between 500Da and 1OkDa of which between 2% and 10% (w/w) is constituted of IGF-1.
[0072] Particularly, the present invention provides the composition as defined herein, wherein the composition is liquid and comprises at least 20 ng/ml of IGF-1 ; a total protein concentration of less than 2% (w/w) and is substantially free of lysozyme and TGF-β. Particularly, the present invention provides the composition as defined herein, wherein IGF-1 is present at at least about 40ng/ml.
[0073] Particularly, the present invention provides the composition as defined herein, wherein the composition is solid (powder) and comprises at least 1 ng of IGF-1 per mg of solid; a total protein concentration of less than 2% (w/w) of protein and is substantially free of lysozyme and TGF-β. Particularly, the present invention
DOCSQUL 756309M
provides the composition as defined herein, wherein IGF-1 is present at at least about 1.6ng/mg total solid.
[0074] Particularly, the present invention provides the composition as defined herein, wherein said peptides below 500Da are present in physiologically effective amounts.
[0075] Particularly, the present invention provides the composition as defined herein, wherein said peptide of MW less than 500Da is selected from the group consisting of: PDGF; FGF; EGF; VEGF; defensins, cathelicidins, anti-microbial peptides (AMP) and proline- rich peptides (PRP). [0076] Particularly, the present invention provides a formulation comprising a composition as defined herein, further comprising a physiologically acceptable excipient; particularly, the formulation is topical or an oral formulation.
EXAMPLES Example 1 -Preparation of composition
[0077] Frozen whole bovine colostrum (less than 48 hrs post-parturition) is slowly thawed to 1O0C until complete melting. The fat fraction is then separated from this raw colostrum using a milk separator. The skimmed colostrum is then heated to 35°C and caseins are precipitated with the addition of double strength microbial rennet (Danisco, Madison, Wl, USA) for 20 minutes. The curds are separated by centrifugation from colostrum whey at 65°C. After the casein fines are removed at 37°C from the colostrum whey with a milk separator, the colostrum whey is heated to 50°C and submitted to an ultrafiltration step using a 10,000 molecular weight cut off (MWCO) spinal wound membrane (Parker Process Advanced Filtration, Oxnard, CA, USA). The ultrafiltration permeate is collected and acidified to pH 3.2. The acidified permeate is then concentrated with nanofiltration. Finally, the concentrated acidified permeate is freeze-dried.
DOCSQUE: 756309M
Example 2-Analysis and composition
Liquid Solid
Proteins <2% <2%
IGF-I 43 ng/mL 1.95 ng/mg total solids
Antimicrobial Presence Presence peptides (<1 O kDa) (<1 O kDa)
Molecular weight distribution (HPSEC)
[0078] Samples were solubilized in HPLC grade water and then filtrated on 0.2μm pore size filters. Samples were then passed trough a TSK-GEL, Guard SWXL (6.0 i.d. x 40 mm) pre-column (Tosoh Biosep LLC, Montgomeryville, PA, USA) and a TSK-GEL, G2000 SWXL (7.8 i.d. x 300 mm) column (Tosoh Biosep LLC, Montgomeryville, PA, USA) at a flow rate of O.δmL/minute using a Waters HPLC (Mississauga, Ont., Can) containing two pumps (model 600), a controller (model 600E) and a UV detector (model 486). The results were analyzed with Millennium 32 software.
DOCSQUE: 756309M
Example 3-Fibroblast functions
[0079] Human fibroblasts were derived from foreskins and used at passages between 10 and 25. They were maintained in Dulbecco's modified Eagle's medium (DMEM, Sigma Chemical Co.) supplemented with 5% FBS and antibiotics/antifungic. For the cultures in the presence of the compositions to be tested the concentration of FBS was decreased to 0.5%. In monolayer and 3-D culture experiments, fibroblasts were seeded for a few hours in the presence of
5%FBS and then rinsed and the medium was changed to 0.5%FBS in the presence of the different concentrations of the compositions to be tested. Cultures were performed in 5% CO2 and humid atmosphere.
[0080] The XTT Cell Proliferation Assay is a colorimetric assay system which measures the reduction of a tetrazolium component (XTT) into soluble formazan product by the mitochondria of viable cells. The samples are read using an ELISA plate reader at a wavelength of 450nm. The amount of color produced is directly proportional to the number of viable cells.
Metabolic activity measurements (XTT assay) in monolayer cell cultures
[0081] XTT (2,3-bis{2methoxy-4-nitro-5-sulfophenyl}-2H-tetrazolium-5- carboxyanilide inner salt) assay was performed according to the manufacturer's procedure (TOX2, Sigma-Aldrich Canada Ltd., Oakville, Ontario). For the XTT assay, cells were seeded at 2.5x104 cells/cm2 for fibroblasts and endothelial cells both in 24 multi-well plates. After 2-4 hrs, cell cultures were rinsed once and media supplemented with only 0.5% FBS containing the different dilutions (1 :1000, 1 :100, 1 :10 and 1 :1 ) of each composition to be tested were introduced. Cells were grown for 4 days with one medium change at day 2. However, each composition was added every day in culture medium. Afterwards, cell cultures were rinsed in PBS. A PBS solution of XTT (1 mg/ml) was mixed with a PBS solution of phenazinemethosulfate and incubated at 370C for 1 hr. Optical densities were then
DOCSQUL 756309M
measured with a fluorometer (Spectra Max 340Pe molecular Devices, Sunnyvale,
CA) set at 450 nm absorbance, and values were subtracted from the blank values. For each condition, cultures were performed in triplicate. In addition, a standard curve of increasing cell densities was used to correlate the optical density value with the cell numbers.
[0082] As demonstrated in Figure 1 , the 1 :1 dilution of the fraction enhanced significantly the cell growth compared to control value (P<0.05). The lowest dilution tested (1 :0.5) did also enhance cell growth significantly in comparison to the control (P<0.05). The highest dilutions tested (1 :10 and 1 :5) were not different from the control value. These data suggest that the present colostrum-derived fraction increased fibroblast metabolic activity in a bell-shape manner with a peak activity at a dilution of 1 :1.
Example 4-Collagen contraction [0083] Fibroblasts were mixed in collagen solution prior to gel formation at a density of 5 x 104 cells per 500μl gel in wells of 24 multiwell plates. Collagen gels were made by mixing a rat tail tendon collagen solution (3.0 mg/ml) with a solution containing culture medium (DMEM 5x sans NaHCO3), FBS, 0.26M NaHCO3, 1 N NaOH and the suspension of cells as previously described by Elsdale & Bard (1972). Briefly the formula was the following:
1ml DMEM 5x without NaHCO3 500μl FBS
500μl NaHCO3 at 0.26M 20μl NaOH at 1 N 100μl H2O
Add 0.88ml cell dispersion (5.7 x 105 cells/ml) and then 2ml rat tail collagen. The mixed solution was transferred to wells. Gels were formed after 15mn incubation. After 2-4hrs of incubation in medium with serum (5%)-supplemented medium, the
DOCSQUE 756309M
medium was changed, cell cultures rinsed and the different compositions were diluted in culture medium supplemented with 0.5% FBS. Composition was introduced daily for 4 consecutive days. Triplicate samples were analyzed. By 24 hrs the gels were released from wells and left floating in order to trigger the collagen contraction by fibroblasts. Medium was changed at day 2. After 4 days, images of the gels were taken and quantified using an image analysis system (Image J). The values of the areas occupied by gels were expressed in mm2 according to scale setting.
[0084] As shown in Figure 2, all dilutions prevent collagen contraction, compared to control value (P<0.05), which suggest that in presence of the colostrum-derived fraction collagen will not contract to form an hypertrophic scar.
Example 5-Collagen synthesis/deposition
[0085] Fibroblasts were seeded at 1x105 cells per well of 6 multi-well plates in serum-supplemented medium. As described earlier, medium was changed after 2- 4hrs of incubation with a low-serum-supplemented (0.5% FBS) medium containing the composition to be tested. Fibroblast cell cultures were labeled by introducing 1.5μCi/ml [3H]-proline (Perkin Elmer) in medium after 4 hrs post-cell seeding and then every other day at medium changes for 7 days in monolayer cell cultures. The labeling medium contained 10μg/ml of ascorbate. At each medium change, media were pooled (medium pool) corresponding to most soluble collagen that has been released form the cells. At day 5, media were pooled with the previous respective pools, and the cell-matrix layers were scraped from wells with a rubber policeman and collected to be pooled (cell-matrix pool). The latter consisted mainly of insoluble collagen that has been deposited by the cells forming the extracellular matrix around the fibroblasts. To avoid any biodegradation during these maneuvers, both pools were treated with a protease inhibitor cocktail (EDTA, NEM, PAB, and PMSF in 1 M TrisHCI at pH 7.5). Pools were then promptly frozen until further use. The two frozen pools were thawed, vortexed, and then dialyzed against water for 3-4 days until the free radioactivity was released as determined by periodic counts. Dialyzed pools
DOCSQUL 756309M
were frozen to be freeze-dried in a freeze-drying apparatus (Labconco). Dried samples were rehydrated in a 4%SDS solution in 5mM TRIS (pH 8.0) while keeping an equal final volume to all samples. For each condition, duplicate samples from the cell-matrix pool and those from the medium pool were counted separately in a liquid scintillation counter (Ultima Gold, Perkin-Elmer). Values were counted in dpm. The compositions were changed on a daily basis for 6 days.
[0086] As shown in Figure 3, the two highest dilutions tests (1 :10 and 1 :5) of the colostrum-derived fraction increased amount of collagen and deposition in the cell- matrix pool rather than releasing it in soluble form. [0087] The effect of the colostrum-derived fraction seems to have two distinct activities depending on its dilutions. The proliferative activity is prone at lower dilutions, whereas collagen metabolic activity is expressed at higher dilutions.
[0088] The colostrum-derived fraction appears to have interesting properties not only on fibroblast growth and synthetic activities, but also on the remodeling of pre- existing collagen. Collagen gel contraction is a phenomenon that has been reported as a physical arrangement of pre-existing collagen fibrils {Guidry and Grinnell, 1985). This is due to direct contact between fibroblasts that adhere strongly to the extracellular matrix and remodel the fibrils. In addition, the collagen synthesis in collagen gel has been found slightly diminished, as well as the DNA replication, compared to that observed in monolayer cell culture (Mauch et ai, 1988; Nusgens et al., 1984). This phenomenon may be largely due to the presence of collagen fibrils around the cells that down-regulate cell activity as observed in normal connective tissue.
[0089] Inhibition or limitation of collagen gel contraction has been reported previously with specific molecules such as prostaglandins E1 and E2, and the incorporation of proteoglycans, heparin, or plasma fibronectin in the collagen gel (Anderson et al, 1990; Guidry and Grinnell, 1987). Serum deprivation is also an important factor as demonstrated also in our assessments. Moreover, it has been reported that high doses of bFGF inhibited collagen gel contraction (Finesmith et al. 1990) whereas TGF-β facilitated it. Withouit wishing to be bound by theory, it is
DOCSQUE: 7S6309M
thought that the present colostrum-derived fraction contains some of these molecules that correspond to antagonist on the matrix contraction and remodelling.
[0090] Since the collagen gel contraction assay is a model relative to the physiopathology of wound healing, scar formation and tissue remodeling, the research and development of agonists and antagonists is incomplete. The present fraction is a potential antagonist product, especially as it facilitates also cell growth and collagen synthesis as shown in specific in vitro experimental conditions. This composition has potential applications in plastic and reconstructive surgery to treat scar tissues. Indeed, recurrence of excessive remodeled scar tissues (e.g., keloids, hypertrophic scar tissues) after surgery represents an important issue. Furthermore, such composition may find application not only in wound healing but also in fibrotic reaction. The present fraction may also find an application in skin ulcers since rebuilding collagen matrix in the wound is also important to consider in such cases.
Example 6- Large open wounds on guinea pigs
[0091] The healing effect of compounds such as the colostrum-derived fraction was studied using a model of large full-thickness open wounds in guinea pigs. This model allows investigating the long term wound healing effect of the colostrum- derived fraction. Since the colostrum-derived fraction is in solution, different dilutions were applied daily for a period of 3 weeks.
[0092] Female Hartley guinea pigs weighing between 250-35Og (3-4 weeks old) were purchased at Charles River. Animals were kept in separate cages, with water and food ad libitum. All animal experiments were performed according to the guidelines of the Canadian Council for Animal Care and approved by our institutional Animal Care Committee.
[0093] The wound model consisted in the creation by scalpel incision of one large open full-thickness wound on each flank of each animal, close to the spinal cord. Each wound area had a 2.5 cm length along the cranio-caudal axis and 2cm large. The whole connective tissue was removed to insure no residue left at the bottom. The animals received, 1hr before surgery, a subcutaneous injection of an analgesic
DOCSQUB: 756309M
(Buprenorphine®, 0.05mg/kg) and a Ringer's lactate solution at a volume corresponding to 1/10th of their weights. The animals were anesthetised by isofluorane under oxygen. Surgery was performed in sterile conditions. The skin was aseptized with hibitane, 70% alcohol, and proviodine. Animals received for 2 days after surgery an analgesic at the same dose as described earlier at 12hrs interval. Animals were weighed periodically at dressing change without the dressing to compare with the initial weight performed one day before surgery. All animals grew in an exponential manner as expected in a normal guinea pig development.
[0094] Thereafter, the respective wound was filled with the solutions to be tested. Five compositionPBS dilutions were tested: 1 ) 1 :0.5, 2) 1 :1 , 3) 1 :10, 4) 1 :100 et 5) 1 :1000. The control animals received PBS. The wounds were then covered with a transparent self-adhesive polyurethane film (Tegaderm®, 3M), followed by a sterile gaze. The trunk of each animal was wrapped with a self-adhesive elastic bandage (Elastoplast®) to maintain the bandage in place and to avoid any trauma. Each animal was identified by a label on its cage. The bandage was left in place and periodically changed at days 5, 9, 14, and 19. A photograph of each wound was taken at days 5, 9, 14 and 23 (last sacrifice). A cm scale ruler and an identified label were inserted in each photograph. Quantification of macroscopic view of the wound areas was performed directly on photographs. Wound contraction
[0095] Wound contraction as measured represents the size of the wound as viewed from above the back of the animals as determined by tracing over the photographs. The trend curves of contraction were generally similar for all conditions, with an important drop by day 9 (Figure 4). At days 5 and 9, there were no significant difference statistically (equal variance test failed). However, statistic analyses (ANOVA and Fisher LSD method) show a significant difference by day 14 in the wounds treated with the 1 :1 and 1 :0.5 dilutions compared to control wounds and those treated with 1 :10 and 1 :1000 dilutions (p<0.05) By day 23, there was also a significant difference between the highest doses (1 :0.5) and control wounds. (Figure 4).
DOCSQUL 756309\l
Wound tissue areas
[0096] As shown in Figure 5 the treatment of large open wound with the composition of the invention increases formation of wound tissue. Quantification of the surface areas occupied by the wound tissue by day 23 showed significant increase with 1 :1 dilution (Fisher LSD method of statistic analysis was used with a failed equal variance test).
Wound thickness
[0097] Quantification of the thickness of the wound tissue also showed a significant increase by day 16 with the wounds treated with 1 :1 dilution compared to control and the lowest dose (1 :1000). By day 23, the thickness of wounds treated with a 1 :100 dilution was significantly higher than the other conditions using the Student- Newman-Keuls method as statistical comparisons methods (normality and equal variance test passed). (Figure 6)
Collagen deposition and density [0098] The composition increased the areas occupied by collagen with a tendency to increase its density. By day 23, there was an increase in surface area occupied by collagen where the composition was applied at a dilution of 1 :100 (Figure 7). However, this increase in surface area was not significantly different compared to control (PBS). Treatment of large open wound with the composition also induced an increased of collagen density compared to control (Figure 8).
Example 7- Subcutaneous implantation of PVA sponges
[0099] The PVA (Polyvinyl alcohol) sponge model is used for studying granulation and reparative tissue ingrowth. Tissue grows within its interstices shortly after implantation. This model is highly reproducible and is a biologically valid model for studying healing responses.
[00100] Spraque Dawley rats were used for this implantation model. A dorsal median incision (rostral) was performed in the skin down to the aponevrosis, and
DOCSQUE: 756309M
then two subcutaneous pockets (one on each side) were made. Each wound area was 1x1 cm. A PVA sponge was introduced in each pocket and the skin was sutured (4/0 monofilaments). Sponges were far from the skin incision to avoid any interference. Specimens were retrieved at days 8 and 15 to see the speed of tissue ingrowth. After 8 and 15 days, implants were retrieved, fixed in formaldehyde and processed for histological sections which was stained with hematoxylin, phloxin, saffron and Hoechst 33342 to mark the nuclei and the sections of day 15 were also stained with picro-sirius to visualize the collagen deposition. Quantification was performed by measuring the length of tissue invasion from the host-implant interface to the invasive front, in multiple areas in a random manner. Moreover, using Hoechst-stained tissue sections, the number of nuclei present in the sponge was counted using the image analysis system and reported to the total surface of the void spaces of PVA sponge present on each histological section. This ratio was used for comparison between the different conditions. [00101] As shown in Figure 9, the composition significantly (p=0.001 ) increases the tissue ingrowth in PVA sponges. An increase of 42% of the tissue growth in PVA sponges was observed in animal treated with the composition. This result demonstrates that the composition of the invention induces tissue formation in wounds.
Example 8- Hypertrophic scar
[00102] Wound healing is a fundamental complex-tissue reaction leading to skin reconstitution. Alterations in the orchestrated wound healing process result in hypertrophic or keloid scarring. Although hypertrophic scarring commonly occurs following burns, many aspects such as incidence of an optimal treatment for scar hypertrophy remain unclear. Hypertrophic scar is associated with polarized Th2 systemic response to injury that leads to increased T cells and their Th2 fibrogenic cytokines in tissues and the development of fibrosis and hypertrophic scars.
Concentration of the composition
DOCSQUE: 756309M
[00103] Bioactive compounds of the composition were concentrated by dehydration with speed-vacuum. The samples were frozen and applied in a speed vacuum with a pressure of 100 milliTorr. A concentration of almost 30 times was achieved. This concentrated fraction was named speed-vaccum IM. [00104] The wound model consisted in the creation by scalpel incision of two open full-thickness wounds on each flank of each animal, close to the spinal cord. Each wound area had a 1x1 cm. If necessary, haemostasis was insured by compression with a gaze and thermocoagulation. The whole connective tissue was removed to ensure no residue left at the bottom. The day of surgery, the animals received, 1 hr before surgery, a subcutaneous injection of an analgesic (Buprenorphine®, 0.05mg/kg) and a Ringer's lactate solution at a volume corresponding to 1/10th of their weights. For surgery, the animals were anesthetised by isofluorane under oxygen. Surgery was performed in sterile conditions. The skin was aseptized with hibitane, 70% alcohol, and proviodine. The respective wound was covered with a polyurethane sheet (Tegaderm) and the animals wrapped in gauzes and elastoplast to protect the wounds for 5 days. After 5 days the dressing was renewed in the same manner. After 15 days, the wounds were left at air-free environment until epithelialisation was almost completed (>90%). This was reached at 19 days and iconography was performed as image prior to treatment. Wounds on each animal were then treated (day 19 corresponds to day 0 of treatment) by speed- vacuum IM and speed-vacuum BSA on one side and on the other side, respectively. Wounds were treated for 14 days by daily application (except Sundays) and photographs were taken at day 7 (Day 26) and at sacrifice at day 14 (day 33). Macroscopic evaluation of the wound area included the scar tissue, thickening of the scar, etc. and microscopic observation with quantification (see Figure 10 for an example).
[00105] Scar formation. As shown in Figure 10, treatment of a wound by the composition reduces scar formation. An untreated wound may lead to the formation of a scar. Indeed, a scar was formed in 7 out of 8 wounds treated with control vehicle (BSA) (Figure 10). However, following 14 days of treatment with the composition, the majority of wounds (5 of 8) have no scar.
DOCSQUE 756309M
[00106] Hypertrophic wound Treatment with the composition prevented the formation of hypertrophic wound (Figure 11) No hypertrophic scar was observed in wounds treated with the composition However, in wounds treated with the BSA (control), hypertrophic wounds were formed (3 out of 8)
DOCSQUL 756309\1
[00107] REFERENCES
1. Armogida SA, Yannaras NM, Melton AL, Srivastava MD. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc. 2004; 25(5):297-304.
2. Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1 ) inhibits adenoviral infection in vitro. Regul Pept. 2001 ; 101(1-3):157-61.
3. Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ 2003; 326:88- 92. 4. Bitar MS, Labbad ZN. Transforming growth factor-beta and insulin-like growth factor-l in relation to diabetes-induced impairment of wound healing. J Surg Res. 1996; 61(1): 113-9.
5. Bitar MS. Insulin and glucocorticoid-dependent suppression of the IGF-I system in diabetic wounds. Surgery. 2000; 127(6):687-95. 6. Blakytny R, Jude EB, Martin Gibson J, Boulton AJ, Ferguson MW. Lack of insulin-like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J Pathol. 2000; 190(5):589-94.
7. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A. 2006; 103(5): 1516-21.
8. Butler AA, LeRoith D. Minireview: tissue-specific versus generalized gene targeting of the igf1 and igfi r genes and their roles in insulin-like growth factor physiology. Endocrinology. 2001 ; 142(5): 1685-8.
9. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. Insulin- like growth factors-binding protein-3 binds to fibrinogen and fibrin J Biol
Chem. 1999; 274(42): 30215-30221.
DOCSQUlI: 756309M
10. Clare DA, Catignani GL, Swaisgood HE. Biodefense properties of milk: the role of antimicrobial proteins and peptides. Curr Pharm Des. 2003; 9(16): 1239-55.
11. Clare DA, Swaisgood HE. Bioactive milk peptides: a prospectus. J Dairy Sci. 2000; 83(6): 1187-95.
12. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw. 2000; 11(2):257-66. 13. Chang TL, Vargas J Jr, DelPortillo A, Klotman ME. Dual role of alpha- defensin-1 in anti-HIV-1 innate immunity. J Clin Invest. 2005; 115(3):765-73.
14. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol. 1993; 55:131-53.
15. De Yang , Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. LL-37, the neutrophil granule- and epithelial cell- derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000; 192(7): 1069-74.
16. Ericksen B, Wu Z, Lu W, Lehrer Rl. Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother. 2005;
49(1 ):269-75.
17. Gauthier SF, Pouliot Y, Maubois JL. Growth factors from bovine milk and colostrum : composition, extraction and biological activities. Lait. 2006; 86: 99-125. 18. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer Rl. Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985; 76(4): 1427-35.
DOCSQUE 756309U
19. Gennaro R, Zanetti M, Benincasa M, Podda E, Miani M. Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. Curr Pharm Des. 2002; 8(9):763-78.
20. Gopal PK, Gill HS. Oligosaccharides and glycoconjugates in bovine milk and colostrum. Br J Nutr. 2000; 84 Suppl 1 :S69-74.
21. Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, Lehrer Rl, Herald BC. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol. 2006; 177(12):8658-66.
22. Hoover DM, Wu Z, Tucker K, Lu W, Lubkowski J. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents
Chemother. 2003; 47(9):2804-9.
23. Howell MD, Jones JF, Kisich KO, Streib JE, GaIIo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol. 2004; 172(3): 1763-7. 24. Janusz M, Lisowski J. Proline-rich polypeptide (PRP)--an immunomodulatory peptide from ovine colostrum. Arch Immunol Ther Exp (Warsz). 1993; 41(5- 6):275-9.
25. Jones Jl, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995 Feb;16(1):3-34. 26. Kelly GS. Bovine colostrums: a review of clinical uses. Altern Med Rev. 2003; 8(4):378-94.
27. Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J 2006; 47(3): 293-306.
28. Lόpez-Garcfa B, Lee PH, Yamasaki K, GaIIo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J
Invest Dermatol. 2005; 125(1 ): 108-15.
29. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, GaIIo RL. Innate antimicrobial peptide
DOCSQUE: 756309M
protects the skin from invasive bacterial infection. Nature. 2001 ;
414(6862):454-7.
30. Okuyama H, Urao M, Lee D, Drongowski RA, Coran AG. The effect of epidermal growth factor on bacterial translocation in newborn rabbits. J Pediatr Surg. 1998; 33(2):225-8.
31. Reddy KVR, Yedery RD, Aranha C. Amtimicrobial peptides: premisese and promises, lnt J Antimicrobial Agents 2004: 24;536-547.
32. Schultz GS, White M, Mitchell R, Brown G, Lynch J, Twardzik DR, Todaro GJ. Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor. Science. 1987; 235(4786):350-2.
33. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999; 341 (10):738-46.
34. Shimasaki S, Ling N. Identification and molecular characterization of insulin- like growth factor binding proteins (IGFBP-1 , -2, -3, -4, -5 and -6). Prog Growth Factor Res. 1991 ;3(4):243-66.
35. Steed DL. Modifying the wound healing response with exogenous growth factors. Clin Plast Surg. 1998; 25(3):397-405.
36. Stewart CE, Rotwein P. Insulin-like growth factor-ll is an autocrine survival factor for differentiating myoblasts. J Biol Chem. 1996; 271 (19): 11330-8. 37. Thapa BR. Therapeutic potentials of bovine colostrums. Indian J Pediatr. 2005; 72(10):849-52.
38. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K,
Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005; 175(7):4662-8.
DOCSQUE 756309U
39. Tsuboi R, Shi CM, Sato C, Cox GN, Ogawa H. Co-administration of insulin- like growth factor (IGF)-I and IGF-binding protein-1 stimulates wound healing in animal models. J Invest Dermatol. 1995; 104(2): 199-203.
40. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003; 83(3):835-70.
41. Wieczorek Z, Zimecki M, Janusz M, Staroscik K, Lisowski J. Proline-rich polypeptide from ovine colostrum: its effect on skin permeability and on the immune response. Immunology. 1979; 36(4):875-81.
42. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 1999; 286(5439):525-8.
43. Yang D, Liu ZH, Tewary P, Chen Q, de Ia Rosa G, Oppenheim JJ. Defensin participation in innate and adaptive immunity. Curr Pharm Des. 2007; 13(30): 3131-9.
DOCSQUE 756309M
Claims
1. A process for the preparation of a colostrum-derived fraction enriched in growth factors, said process comprising the steps of: a) precipitating casein from colostrum and separating curds from colostrum whey; b) heating said colostrum whey to a temperature of greater than 4O0C; c) submitting said heated whey to ultra-filtration with a molecular weight cutoff of about 14kDa or less and collecting permeate; d) acidifying said permeate obtained in step c) to a pH of between 3 and 4.
2. The process according to claim 1 , wherein said colostrum in step a) is obtained from thawing frozen whole colostrum to a temperature of at least about 40C.
3. The process according to claim 2, wherein said colostrum in step a) is obtained from thawing frozen whole colostrum to a temperature of about 1O0C.
4. The process according to claim 1 , wherein, in step a), said casein and curds are separated by treatment with microbial rennet or by acid treatment.
5. The process according to claim 4, wherein, in step a), said casein and curds are separated by treatment at pH 4.6.
6. The process according to claim 1 , wherein the acidified permeate obtained in step d) is concentrated to obtain a concentrated liquid fraction.
DOCSQUL 756309M
7. The process according to claim 6, wherein the concentrated liquid fraction is freeze-dried to obtain a solid fraction.
8. The process according to claim 1 , wherein in step b), said colostrum whey is heated to a temperature of at least 450C.
9. The process according to claim 8, wherein in step b), said colostrum whey is heated to a temperature of about 5O0C.
10. The process according to claim 1 , wherein in step c), said heated whey is submitted to ultra-filtration with a molecular weight cut-off of about 12kDa or less.
11. The process according to claim 10, wherein in step c), said heated whey is submitted to ultra-filtration with a molecular weight cut-off of about 1OkDa.
12. The process according to claim 1 , wherein in step d) the permeate is acidified at a pH of about 3.5.
13. The process according to claim 12, wherein in step d) the permeate is acidified at a pH of 3.2.
14. The process according to claim 6, wherein the acidified permeate is concentrated with nanofiltration or any other concentrating method.
DOCSQUE 756309M
15. The process according to claim 1 , wherein said colostrum is obtained from: cow, ewe, jenny (donkey's female); goat or buffalo.
16. A composition derived from colostrum comprising at least 60% of antimicrobial peptides of MW less than 500Da; IGF-1 and a total protein concentration of less than 5% (w/w).
17. The composition according to claim 16, comprising at least 70% of antimicrobial peptides of MW less than 500Da and further comprising at least 20% (w/w) of antimicrobial peptides of molecular weight between 500Da and 1OkDa of which between 2% and 10% (w/w) is constituted of IGF-1.
18. The composition according to claim 16, wherein the composition is liquid and comprises at least 20 ng/ml of IGF-1 ; a total protein concentration of less than 2% (w/w) and is substantially free of lysozyme and TGF-β.
19. The composition according to claim 18, wherein IGF-1 is present at at least about 40ng/ml.
20. The composition according to claim 16, wherein the composition is solid and comprises at least 1 ng of IGF-1 per mg of solid; a total protein concentration of less than 2% (w/w) of protein and is substantially free of lysozyme and TGF-β.
21. The composition according to claim 20, wherein IGF-1 is present at at least about 1.6ng/mg total solid.
DOCSQUE 756309U
22. The composition according to claim 16 or 17, wherein said peptides below
500Da are present in physiologically effective amounts.
23. The composition according to claim 16 or 17, wherein said peptide of MW less than 500Da is selected from the group consisting of: PDGF; FGF; EGF; VEGF; defensins, cathelicidins, anti-microbial peptides (AMP) and proline- rich peptides (PRP).
24. A formulation comprising a composition according to claim 16 or 17, further comprising a physiologically acceptable excipient.
25. The formulation according to claim 24, wherein said formulation is topical.
26. The formulation according to claim 24, wherein said formulation is an oral formulation.
27. Use of the composition according to claim 16 or 17, for the manufacture of a formulation for the treatment of a wound and/or facilitating and/or accelerating wound healing while inducing minimal collagen contraction.
28. A method for healing a wound while inducing minimal collagen contraction, said method comprising treating said wound with the formulation according to claim 24.
29. A method for treating skin injury and ulcers comprising application to the wound with the liquid composition "as is" or with the formulation as defined in claim 24.
DOCSQUE: 756309M
30. A method for accelerating wound healing and improving aesthetical presentation of the scars formed in the wound healing process, the method comprising application on the wounded skin an effective amount of a formulation as defined in claim 24.
DOCSQUE 756309M
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2722821A CA2722821A1 (en) | 2008-05-07 | 2009-05-06 | Colostrum-derived fraction for wound healing and skin care |
EP09741624A EP2296673A1 (en) | 2008-05-07 | 2009-05-06 | Colostrum-derived fraction for wound healing and skin care |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5117908P | 2008-05-07 | 2008-05-07 | |
US61/051,179 | 2008-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009135306A1 true WO2009135306A1 (en) | 2009-11-12 |
Family
ID=41264373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2009/000627 WO2009135306A1 (en) | 2008-05-07 | 2009-05-06 | Colostrum-derived fraction for wound healing and skin care |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2296673A1 (en) |
CA (1) | CA2722821A1 (en) |
WO (1) | WO2009135306A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2417857A1 (en) * | 2010-08-12 | 2012-02-15 | LR Health & Beauty Systems GmbH | Method for manufacturing a colostrum product and device for executing the method |
WO2016020284A1 (en) * | 2014-08-06 | 2016-02-11 | Tenagro S.R.L. | Process for the preparation of high purity mixtures of protein factors from bovine colostrum |
US10385094B2 (en) | 2017-07-26 | 2019-08-20 | Dustin Kjelden | Colostrum solid extraction process |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029518A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Isolation of growth and differentiating factors from colostrum |
-
2009
- 2009-05-06 WO PCT/CA2009/000627 patent/WO2009135306A1/en active Application Filing
- 2009-05-06 EP EP09741624A patent/EP2296673A1/en not_active Withdrawn
- 2009-05-06 CA CA2722821A patent/CA2722821A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029518A1 (en) * | 2004-09-14 | 2006-03-23 | Nexcell Biosciences Inc. | Isolation of growth and differentiating factors from colostrum |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2417857A1 (en) * | 2010-08-12 | 2012-02-15 | LR Health & Beauty Systems GmbH | Method for manufacturing a colostrum product and device for executing the method |
WO2016020284A1 (en) * | 2014-08-06 | 2016-02-11 | Tenagro S.R.L. | Process for the preparation of high purity mixtures of protein factors from bovine colostrum |
US10385094B2 (en) | 2017-07-26 | 2019-08-20 | Dustin Kjelden | Colostrum solid extraction process |
Also Published As
Publication number | Publication date |
---|---|
EP2296673A1 (en) | 2011-03-23 |
CA2722821A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10717763B2 (en) | Compositions containing HC-HA/PTX3 complexes and methods of use thereof | |
EP3237622B1 (en) | Methods for wound healing | |
US20060286157A1 (en) | Protein mixtures for wound healing | |
Bankoti et al. | Carbon nanodot decorated acellular dermal matrix hydrogel augments chronic wound closure | |
CN101730540A (en) | Wound healing compositions containing keratin biomaterials | |
EP0443224B1 (en) | Use of thrombospondin to promote wound healing | |
US8455443B2 (en) | Methods of use of skin wound healing compositions | |
US20110312891A1 (en) | Enamel matrix derivative fraction c | |
EP2296673A1 (en) | Colostrum-derived fraction for wound healing and skin care | |
Lee et al. | Expression, purification and osteogenic bioactivity of recombinant human BMP-2 derived by Escherichia coli | |
US20080038374A1 (en) | New Use | |
WO2012060832A1 (en) | Skin wound healing compositions and methods of use thereof | |
WO2015012682A2 (en) | A method for extracting collagen from aquatic animals, collagen and products containing it | |
US10434213B2 (en) | Controlled delivery system | |
JP2010515679A (en) | Short bioactive peptides for cell and immune regulation | |
JP4726300B2 (en) | Matrix protein composition for transplantation | |
WO2011073447A9 (en) | Emd c-depleted | |
CA2581693A1 (en) | New use | |
CN116036247B (en) | Composition for inhibiting inflammatory response, promoting angiogenesis and wound healing and application thereof | |
US20230173135A1 (en) | Process to coat a medical device surface with peptide-based nanoparticles | |
Bhawal et al. | The pro-healing effect of protamine-hydrolysate peptides on skin wounds involves TGF-β/Smad signaling | |
WO2014177602A1 (en) | Trap 63 | |
Buff-Lindner | The Role of Poly N Acetyl Glucosamine Nanofibers in Cutaneous Wound Healing | |
WO2003035692A2 (en) | Modified peptides and their uses | |
WO2011085182A2 (en) | Biological surfactants for connection to silicone-based materials and modulating levels of immunologically active proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09741624 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2722821 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 588990 Country of ref document: NZ |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009741624 Country of ref document: EP |